Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting

Bone Marrow Transplantation

Volumn 44, Issue 4, 2009, Pages 237-242

  Bregni, M ^a,b   Bernardi, M ^a   Servida, P ^a,c   Pescarollo, A ^a,d   Crocchiolo, R ^a   Treppiedi, E ^a   Corradini, P ^a,e   Ciceri, F ^a   Peccatori, J ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b San Giuseppe Hospital   (Italy)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^d Ospedale Evangelico Internazionale   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; RAPAMYCIN; THIOTEPA;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; KIDNEY CANCER; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 69749119573     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.9     Document Type: Article

References (20)

1. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
2. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al. Transplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008; 5: 256-267.
3. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006; 17: 1134-1140.
4. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005; 104: 2099-2103.
5. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 5601-5608.
6. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
7. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34 Series B: 187.220-226.
8. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001; 28 909-915. Part II: Regression modelling. Bone Marrow Transplant 2001; 28: 1001-1011.
9. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003.
11. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463.
12. Takahashi Y, Harashima N, Kajigaya SH, Yokoyama H, Cherkasova E, McCoy JP et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008; 118: 1099-1109.
13. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
14. Hudes G, Carducci M, Tomczac P, Dutcher J, Figlin R, Kapoor A et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
15. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
16. Motzer RJ, Hutson TE, Tomczac P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
17. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
18. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
19. Suppiah R, Finke J, Rini BI, Richmond A, Wood L, Elson P et al. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during Sunitinib treatment: Correlation with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. J Clin Oncol 2006; 24: 1065a.
20. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453-462.